What the FDA labels say about taking them together
Chlorpromazine and pimavanserin
Pimavanserin's FDA label of June 18, 2026 names chlorpromazine in its warnings and precautions section; chlorpromazine's label does not name pimavanserin itself but warns about its class (Atypical antipsychotics). The pimavanserin label: “The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain …”
Check it at the source: the chlorpromazine FDA label on DailyMed (effective May 12, 2026, Amneal Pharmaceuticals NY LLC); the pimavanserin FDA label on DailyMed (effective June 18, 2026, Acadia Pharmaceuticals Inc.).
What does the chlorpromazine label say about pimavanserin?
Chlorpromazine's label does not name pimavanserin itself; it warns about its class (Atypical antipsychotics):
Chlorpromazine label, boxed warningAnalyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients.
Chlorpromazine label, boxed warningWARNING Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
Source: FDA drug label (CHLORPROMAZINE HYDROCHLORIDE), Amneal Pharmaceuticals NY LLC, effective May 12, 2026 (SPL set aa086a21-de85-4b03-af58-49b70acf8cf0), via openFDA; the full label on DailyMed
What does the pimavanserin label say about chlorpromazine?
Pimavanserin label, warnings and precautionsThe use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin, moxifloxacin) [see Drug Interactions (7.1) ].
Source: FDA drug label (NUPLAZID), Acadia Pharmaceuticals Inc., effective June 18, 2026 (SPL set 1e6bea44-57d6-4bac-9328-46e1ee59f83b), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Chlorpromazine | Pimavanserin | |
|---|---|---|
| Labeled for | Schizophrenia, Nausea and vomiting | n/a |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.552 per tablet 100 mg tablet | $170.50 per capsule 34 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once